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Traumatic  vascular  injuries  to the  lower  limb  are  frequent  in  athletes,  particularly  in sports  character-
ized  by  high-speed  collisions.  However,  the diagnosis  is not  always  straightforward,  for the  lack  of clearly
visible  abnormalities  without  provocative  testing  or  appropriate  imaging.  The failure  of an early  diagno-
sis  can  lead  to  devastating  consequences.  In these  subjects,  it may  be  useful  to  investigate  the  personal
susceptibility  to thrombotic  events  such  as  the presence  of  a  hereditary  hypercoagulable  state.  We  expe-
rienced  a case  of a soccer  player  with  progressive  swelling  and  severe  pain  of  the  calf after  a  trauma
during  a football  match  3 days  previously,  who  came  to our hospital  for suspected  deep  vein  thrombo-
sis,  conﬁrmed  by  echo-Doppler  ultrasound.  A  thrombophilia  screening  detected  a double  heterozygosityrothrombin G20210A mutation for  factor  V Leiden  and  prothrombin  G20210A  mutation  in  the  presence  of  a strong  family  history  for
thromboembolism.  Immediate  treatment  with  elastic  stocking  compression  and  enoxaparin  was  started.
The  patient  was  discharged  on  warfarin  therapy  maintained  for six  months,  with  the  warning  to  avoid
trauma  activities  during  anticoagulation.  Thrombotic  genetic  testing  in  athletes  who  experience  episodes
of  deep  vein  thrombosis  might  offer important  opportunities  for  patient  management,  such  as prolonged
 avoid
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Venous thromboembolism is a typical multifactorial disease, in
hich genetic testing for inherited causes of thrombophilia, when
linically indicated, is an important component of patient care [1].
n 2003, the US Food and Drug Administration approved the ﬁrst
NA-based laboratory tests speciﬁcally for factor V Leiden and pro-
hrombin G20210A mutation, the most common causes of inherited
hrombophilia.
Deep vein thrombosis (DVT) of the limb after a strenuous exer-
ise or trauma is a rare but well-recognized condition. Athletes,
lso during non-competitive sports, are susceptible to a variety
f vascular injuries because of exposure to high-speed collisions
2]. However, extremity pain in these subjects seldom results
n a diagnosis of venous or arterial abnormalities, although an
arly recognition and aggressive treatment of these disorders has
een recommended to avoid the long-term limb-threatening impli-
 DOI  of commentary article: http://dx.doi.org/10.1016/j.jccase.2012.08.006.
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cations [3]. In these subjects, the identiﬁcation of the personal
susceptibility to thrombotic complications and, in particular, the
screening of factor V and prothrombin mutations that are strong
hereditary risk factors for venous thromboembolism, may  be clin-
ically useful [4].
We  describe a case of a trauma-associated DVT in an ama-
teur football player double heterozygous for factor V Leiden and
G20210A prothrombin mutations, who presented with a strong
family history of venous thromboembolism.
Case report
We  report the case of a 63-year-old man  referred to our cardio-
vascular ultrasound laboratory for progressive swelling of the left
calf after a blunt trauma during a football match 3 days before.
He  denied experiencing any sensation of acute pain and was
able to continue the game with only minor discomfort. On day 1
post-trauma, the patient suffered severe pain in his left leg and
underwent physical therapy with massage of the leg. Because of
lack of relief of symptoms and progressive swelling of the limb he
came to our hospital with suspected DVT.
vier Ltd. All rights reserved.
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Fig. 1. (A) Short-axis view of posterior tibial vein dilated and totally occluded by hyperechoic thrombus. (B) Short-axis view and (C) long-axis view of posterior tibial vein
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athletes, particularly in sports characterized by high-speed colli-
sions such as soccer [2,3]. DVT in such circumstances may  not be
a rare occurrence as a direct consequence of sport-induced trauma
[3]. However, very few cases of lower extremity DVT involving
Table 1
Thrombosis/thrombophilia-related parameters.
Coagulation proﬁle Results Reference range
Activated protein C resistance 1.77 2.61–3.32
Protein C activity (%) 116.3 70–140
Protein S activity (%) 124.81 64.4–128.8
Antithrombin III (%) 84 80–120
Prothrombin factor II (%) 134.2 79–131
Prothrombin time (INR) 0.98 0.8–1.20
Activated partial
thromboplastin time (ratio)
1.01 0.8–1.3
Fibrinogen (mg/dl) 234 170–410
D-dimer (ng/ml) 1540 <400
Homocysteine (mol/l) 10 0–15
Lupus anticoagulant Negativeilated and partially occluded by hyperechoic thrombus (white arrow) and partial 
ecanalization (dashed arrow).
At the examination, the affected leg appeared swollen, hot and
ainful, and also showed positivity to Homans maneuver (pain in
he calf during passive dorso-felxion of the foot), the sign of Neuholf
decrease of calf tossing with the patient’s leg relaxed and ﬂexed
n thigh) and the sign of Bauer (pain provoked by palpation of the
eel, foot, and calf). A lower extremity echo-Doppler ultrasound
onﬁrmed the suspected diagnosis showing dilatation and occlu-
ion of the medial branches of the posterior tibial vein that was  not
ompressible, with no ﬂow inside and thrombotic material (Fig. 1A).
he D-dimer result was suggestive for a suspected thrombo-
is (1540 ng/ml; normal value < 400 ng/ml). Immediate treatment
ith elastic stocking compression and enoxaparin (0.1 UI/kg) was
tarted and after a few days the warfarin therapy was  initiated.
The  patient was an old football player and denied any throm-
otic risk factors. He had undergone meniscectomy with only
ne-day heparin therapy after surgery, without any clinical con-
equences, a few years previously.
Interestingly, his family history was strongly positive for throm-
oembolic events, since his father suddenly died at the age of 52
ears during sleep after a probable thromboembolic event a few
ays after upper limb trauma treated with immobilization and limb
ompressive bandage without any prophylaxis.
In our patient, a thrombophilia screening detected a double
eterozygous genotype for factor V Leiden (FVL) and prothrom-
in G20210A (PT G20210A) mutation. MTHFR C677T variant was
bsent. Other laboratory tests (protein C, protein S, antithrombin
II) were within the normal range. The level of factor II was  134.2%
normal values 79–131%). As expected, he was resistant to activated
 protein (1.77; normal values 2.61–3.32). No lupus anti-coagulants
ere found (Table 1).
The patient was discharged on warfarin therapy (with target
nternational normalized ratio between 2 and 3) and was main-
ained for six months, with the warning to follow-up with his
hysician for regular monitoring, and to avoid traumatic activi-
ies during anticoagulation. Moreover, he was educated about his
ereditary hypercoagulable state, and in particular his high risk of
VT recurrence, with the advice to perform the genetic test to hislization (dashed arrow). (D) Short-axis view of posterior tibial vein with complete
ﬁrst-degree relatives. The results of the family genetic screening
are shown in Fig. 2. All mutated subjects are asymptomatic.
At the follow up, we found in our patient progressive evolu-
tion of thrombus with partial recanalization of the vessel (Fig. 1B
and C) and ﬁnally with retraction of the thrombus and complete
recanalization of the vessel (Fig. 1D).
Discussion
This study demonstrated the importance of considering hered-
itary prothrombotic risk factors in an otherwise healthy subject
with a strong family history of thrombosis who  suffered DVT after
sport-related extremity trauma.
Traumatic vascular injuries to the lower limb are frequent inThrombophilia genetic variants
Factor V Leiden Arg/Gln heterozygous
Prothrombin G20210A G/A heterozygous
MTHFR C677T C/C wild-type
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tig. 2. Pedigree of the family: individuals are identiﬁed by generation and pedigree
utated  genotype. The subjects with a thrombotic episode are represented by ﬁlled
irect sport-associated trauma are reported in the medical liter-
ture [5–9]. From these, there is one case report that speciﬁcally
elated DVT development to soccer-related trauma [5], and a case of
 42 year-old male semi-professional soccer player who sustained
 right lower extremity popliteal contusion during a soccer game
esulting in a traumatic DVT [6]. Moreover, lower extremity DVT
as described in a soccer player with coagulation deﬁciencies [9].
he diagnosis of lower limb vascular injuries in healthy athletes is,
n fact, not always straightforward, because classic symptoms, such
s leg pain or swelling, are often not distinguishing and vascular
njuries are unrecognized probably due to the lack of clearly visible
bnormalities without provocative testing or appropriate imaging
3,10]. The failure of an early diagnosis, and then of appropriate
nticoagulation therapy, can lead to devastating consequences for
thletes [3].
In  these subjects, it may  be useful to investigate the personal
usceptibility to thrombotic events such as the presence of a hered-
tary hypercoagulable state [4]. At the moment, controversy exists
egarding the extent of prothrombotic genetic testing in a young,
therwise healthy athlete diagnosed with a DVT in whom no addi-
ional risk factors for thromboembolism are present [3,11].
In  our patient, the presence of a trauma-associated DVT and of a
trong family history of thromboembolism directed us to perform
enetic testing of prothrombotic mutations, identifying a condition
f high thrombotic risk such as the presence of a double heterozy-
osity for FVL and PT G20210A.
In general, it is considered that the carrier state for more than
ne inherited genetic defect enforces gene penetration and event
anifestation and increases the risk of disease through stratiﬁ-
ation of multiple gene effects. FVL mutation has been found to
nteract with PT G20210A variant contributing to increasing the risk
f the incidence of thromboembolic events and recurrent events.
Heterozygous  carriers of FVL and the PT G20210A gene muta-
ion have, respectively, a 5- and 3-fold higher risk for ﬁrst venous
hrombosis compared to the general population [12,13]. Notewor-
hy, the presence of double heterozygosity for FVL and PT G20210A,
 rare event with an incidence of ≈0.1%, is associated with an 18-
o 20-fold higher risk of DVT compared with non-carriers [14].
oreover, patients with prothrombotic mutations, especially dou-
le heterozygosity, are at increased risk of recurrent DVT compared
ith patients with DVT without these mutations [15–17].
However, uncertainty remains about the contribution of
hese genetic factors for the individualized risk assessment tober. The proband is indicated by arrow and the grey dot indicates the presence of a
bol. The question mark indicates the individuals not genetically tested.
thrombotic  events as the interaction of complex combinations of
variants of different genes with environmental factors may be rel-
atively unpredictable at an individual level. Understanding the
interaction and confounding effect of different factors is a target
for research to maximize treatment beneﬁts and minimize disease
and treatment-associated risks.
In particular, the optimal duration of oral anticoagulant therapy
after a ﬁrst episode of DVT is still controversial. When anticoagu-
lant treatment is stopped after an appropriate duration (at least 3
months), the incidence of recurrent DVT varies according to the
individual risk factors associated with the initial event. Genetic
testing of prothrombotic variants might be used to identify indi-
viduals in a “low-risk” cohort (e.g. a traumatic provoked ﬁrst event)
who might have an atypically high risk of recurrence and therefore
might beneﬁt from continued anticoagulation.
In fact, according to the American College of Chest Physicians
Consensus on Antithrombotic Therapy, homozygous for FVL or
PT mutation, or double heterozygous are candidates for extended
long-term anticoagulation [18].
In our case, the detection of a strong prothrombotic state may be
of crucial importance in an otherwise “low-risk” 63-year-old male,
with post-traumatic DVT and without history of previous throm-
botic events, in which the duration of anticoagulant therapy would
remain controversial.
Conclusions
This  case report supports the need for further studies in order to
investigate the role of prothrombotic mutations in trauma-related
thrombosis. Furthermore, our ﬁndings indicate the importance of
considering testing for inherited thrombotic mutations in athletes
who experienced episodes of DVT in order to improve treatment
and to decrease the risk of recurrence, especially in the presence of
a strong family history for thrombosis and in the absence of other
known risk factors.
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